Overview

The Neurofibromatosis Therapeutic Consortium (NFTC) brought together four labs to find novel targets for clinical trials. This three-year, $4 million collaboration was co-funded with NTAP (Neurofibromatosis Therapeutic Acceleration Program) and was an extension of the Neurofibromatosis Preclinical Consortium (NFPC), a five-year, $7 million program that concluded in 2013. These two consortia cooperated to perform and complete 111 preclinical trials across different models. These studies identified 12 drug targets with promising efficacy, and 16 clinical trials have occurred based on the veracious preclinical data gathered by NFPC and NFTC investigators.

NFTC (2013 – 2016)

The NFTC (NF Therapeutic Consortium) was launched at the conclusion of the NFPC as a three year $4 million program to follow up the work of the NFPC. The NFTC was focused on NF1 and included sites investigating animal models of plexiform neurofibromas, MPNSTs, and NF1- associated leukemia. To continue the NFPC’s work on NF2, the Foundation launched the Synodos initiative.

NFTC Centers

  • Benjamin Braun, MD, PhD and Kevin Shannon, MD, University of California, San Francisco
  • Karen Cichowski, PhD, Harvard Medical School/Brigham and Women’s Hospital
  • D. Wade Clapp, MD, Indiana University School of Medicine
  • Nancy Ratner, PhD, Cincinnati Children's Hospital Medical Center

NFPC (2008 – 2013)

The NFPC was designed to identify and evaluate promising drug candidates for clinical trials through the collaborative efforts of the best academic scientists working on preclinical systems of various NF-associated tumors. The NFPC included sites investigating animal models for both NF1 and NF2.

NFPC Centers

  • Karen Cichowski, PhD, Harvard Medical School/Brigham and Women’s Hospital
  • Kevin Shannon, MD, University of California, San Francisco
  • Timothy Cripe, MD, PhD, Cincinnati Children’s Hospital Medical Center
  • D. Wade Clapp, MD, Indiana University School of Medicine
  • D. Bradley Welling, MD, PhD, Ohio State University
  • Jonathan Chernoff, MD, PhD, Fox Chase Cancer Center

What Now?

Building on these tremendous successes and the validation of the approach, our preclinical consortium is moving forward with a new model that fosters a collaborative research partnership with industry that is interested in testing compounds. If you are interested in more information about the consortium or participating in the program, please indicate your interest by contacting the Managing Director, Hyerim Lee, PhD, at hlee@ctf.org.